The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.
Check-Cap has a new spin on capsule endoscopy, using X-rays instead of a visual camera. But more compelling clinical data will be necessary if it is to position its device as a first-line screen.
Pfizer is to push Exact’s cancer test in a deal that could “permanently alter the trajectory of Cologuard”.
Many small groups are up thanks to takeover speculation, and this may end up being self-defeating.